Digital Silk Announces U.S. Companies Prioritize Custom Web Development to Meet Accessibility and SEO Demands
Miami, Florida--(Newsfile Corp. - May 28, 2025) - Digital Silk, an award-winning web development company focused on creating brand strategies, custom websites and digital marketing campaigns, is announcing a surge in client demand for custom web development projects that prioritize both accessibility compliance and search engine performance.
The intersection of accessibility compliance and SEO in custom web development for U.S. businesses.
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10732/253562_266b43e014520963_001full.jpg
With the tightening of ADA and WCAG regulations in the U.S., alongside Google's continued emphasis on Core Web Vitals, 2025 has seen businesses across sectors turning to custom solutions to ensure their websites meet these rising standards. According to a report from WebAIM, over 96% of homepages tested in 2024 had detectable WCAG 2 failures - a gap that brands are increasingly eager to close to reduce legal risks and improve user inclusivity.
At the same time, Google's Core Web Vitals updates are driving heightened scrutiny of web performance, particularly around loading speed, interactivity, and visual stability. A 2024 survey by Search Engine Journal reported that 68% of U.S. marketers cite Core Web Vitals as a top SEO priority. The overlap between accessibility improvements (such as clear navigation and keyboard-friendly design) and SEO practices (like optimized structure and mobile responsiveness) have positioned custom web development as a critical solution for modern digital teams.
Integrating Accessibility, SEO, and Performance
Digital Silk has responded by offering integrated services that address:
ADA/WCAG compliance audits and remediation
Core Web Vitals optimization across design and development
SEO-focused site architecture and content enhancements
Custom CMS solutions enabling ongoing compliance and performance tracking
These combined efforts are helping companies with processing digital assets against regulatory and search engine shifts.
"Accessibility and SEO are no longer separate conversations," says Gabriel Shaoolian, CEO of Digital Silk. "In 2025, businesses recognize that a compliant, high-performing website can potentially boost organic visibility, improve user engagement and reduce bounce rates."
Market Growth Highlights
Core Web Vitals have become a defining metric for over 85% of SEO agencies and in-house teams according to industry research (source).
Websites failing accessibility standards face rising litigation, with 4,605 ADA lawsuits filed in federal court in 2023 alone (source).
Why Custom Development is Leading the Way
Companies are increasingly turning to agencies like Digital Silk to deliver the combined demands of accessibility, Core Web Vitals, and SEO as well as fully customized builds that align with technical, legal, and marketing goals.
About Digital Silk
Digital Silk is an award-winning Miami web development company focused on growing brands online. With a team of seasoned experts, Digital Silk delivers industry-leading digital experiences through strategic branding and cutting-edge web design with the aim to drive more conversions and digital marketing services to boost awareness and engagement.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
32 minutes ago
- CTV News
Foreign companies eye U.S. expansion to lessen fallout from tariffs
A Honda logo is seen on a Honda accord vehicle at a parking lot in Arlington Heights, Ill., Tuesday, May 21, 2024. (AP Photo/Nam Y. Huh) Some non-U.S. companies have said they are looking at expanding their presence or setting up shop in the United States to mitigate the impact of President Donald Trump's tariffs. Below are some of the plans flagged by those companies. ASM International The Dutch chip-making equipment supplier has started local production of tools for U.S. chipmakers in response to the U.S. tariffs backdrop, its CEO said in May. Barry Callebaut The chocolate maker is planning to increase its U.S.-based production to fend off effects of the 'disruptive environment,' its CEO said in April. BMW BMW is considering adding shifts to its Spartanburg plant in South Carolina to boost output by up to 80,000 units, company executives said in April. Campari The Italian spirits group is assessing opportunities to expand U.S. production, its CEO said in March. Compal Electronics The Taiwanese contract laptop maker may expand into the U.S. and has spoken to several southern states about a possible investment, its CEO said in January. Honda The Japanese carmaker plans to move some car production from Mexico and Canada into the U.S., aiming to make 90% of cars sold in the country locally, the Nikkei reported in April. Hyundai Motor The South Korean automaker plans to further localize production in the U.S. and make hybrid vehicles at its new factory in Georgia, it said in January. It added in April that the production of some Tucson crossovers has been shifted from Mexico to the U.S. and the company is considering moving production of some U.S.-bound cars from South Korea to other locations. Illycaffe The Italian premium coffee maker will look at building a plant in the U.S. if it gets caught up in tariffs, its CEO said in April. Inventec The Taiwanese company, which makes AI servers that use Nvidia chips, has agreed to invest up to US$85 million to build manufacturing facilities in Texas, it said in April. IQE The British semiconductor company is looking at moving some production to the U.S. to guard against potential duties, its CEO said on May 13. Lavazza The Italian coffee maker is pressing ahead with U.S. expansion, it said in April, aiming to produce locally 100% of what it sells in the U.S., from around 50% presently. LG Electronics The electronics giant is considering moving the manufacturing of refrigerators from Mexico to its factory in Tennessee, a South Korean newspaper reported in January. Luxshare The Apple supplier is looking into shifting more production outside China, including into the U.S., its chairwoman said in April. LVMH The luxury conglomerate is 'seriously considering' bulking up U.S. production capacities, its CEO said in January. Mercedes The German carmaker will add production of its GLC SUV for North America to its plant in Tuscaloosa, Alabama, it said in May. Nissan The Japanese automaker might move production of its Sentra automobile from Mexico to the U.S., Automotive News reported on May 14. The Nikkei relayed in April that Nissan was also considering shifting some domestic production of U.S.-bound vehicles there. Novartis The Swiss drugmaker plans to spend $23 billion to build and expand 10 facilities in the U.S., it said in April. Pirelli The Italian tire maker wants to invest further in the U.S. but its plans are on hold due to tensions linked to having Chinese state-owned group Sinochem as its largest investor, it said in April. Roche The Swiss pharma giant will invest $50 billion in the U.S. over the next five years, creating more than 12,000 jobs, it said in April. On May 12, it announced an additional $550 million investment to expand its Indianapolis diagnostics manufacturing hub. Samsung Electronics The tech giant is considering moving manufacturing of dryers from Mexico to its plant in South Carolina, Korea Economic Daily reported in January. Sanofi The French drugmaker plans to invest at least $20 billion in the U.S. through 2030 to boost manufacturing and research, it said in May. Stellantis The Chrysler parent is planning to build a new midsize pickup truck in Belvidere, Illinois, it said in January. TSMC The Taiwanese chipmaker is planning to build five chip facilities in the U.S. in coming years, its CEO said in March. Volkswagen Volkswagen's CFO said in January it planned to produce more in the U.S. Its Audi brand will expand production in North America and will make a decision on where to base itself this year, Audi CEO said in February. VW is holding talks with the U.S. government on tariffs, the CEO said in May. Volvo Cars Volvo Cars may move some production to the U.S. depending on tariffs, its CEO said in March. Compiled by Tomasz Kanik and Vera Dvorakova in Gdansk; Editing by Milla Nissi-Prussak and Elaine Hardcastle, Reuters
Globe and Mail
an hour ago
- Globe and Mail
Palantir Just Landed a Fannie Mae Deal. Should You Buy PLTR Stock Here?
Valued at a market cap of $292 billion, Palantir (PLTR) is among the largest tech companies in the world. PLTR stock has surged close to 500% in the last 12 months and has rallied over 1,200% since its initial public offering in September 2020. Investors and analysts are bullish on Palantir due to its accelerating revenue growth, improving profit margins, a widening portfolio of products, and expanding corporate partnerships. Earlier this week, Fannie Mae (FNMA) launched an AI-powered Crime Detection Unit in partnership with Palantir to combat mortgage fraud in the U.S. housing market. The new platform utilizes artificial intelligence and machine learning to analyze millions of datasets, finding previously undetectable fraudulent patterns. Early testing demonstrated the technology's effectiveness, identifying fraud in seconds that previously took human investigators two months to discover. The partnership initially focuses on Fannie Mae's multifamily housing business, with potential expansion to Freddie Mac (FMCC) under consideration. Fannie Mae, which holds over $4.3 trillion in assets and owns or guarantees approximately 25% of single-family mortgages and 20% of multifamily mortgages nationally, believes this technology will save millions in fraud losses while protecting lenders, homebuyers, and taxpayers. Palantir Is Gaining Traction in AI Palantir recently announced two major partnerships expanding AI capabilities across the government and financial services sectors. Palantir's FedStart program will enable Anthropic's Claude AI application to serve millions of federal employees at FedRAMP High and DoD Impact Level 5 security standards. This collaboration, hosted on Google Cloud (GOOGL) with multi-cloud flexibility through Amazon (AMZN) Bedrock and Vertex AI, will allow government workers to use Claude for writing, data analysis, and complex problem-solving while maintaining strict security compliance. The partnership builds on last year's agreement, where Anthropic partnered with Palantir through AWS for Impact Level 6 accredited environments. Palantir also partnered with xAI and TWG Global (TWG) to revolutionize AI adoption in the financial services sector. The collaboration addresses the critical issue that 74% of companies remain stuck in proof-of-concept phases, yielding no meaningful returns. Its offering includes governance foundations, industry-tuned AI agent suites, and modular agentic workforces designed to deliver measurable business outcomes within 90 days' Unlike traditional per-seat licensing models, the partnership operates on an outcome-based pricing model, aligning success with measurable results. The initiative combines xAI's advanced models and Colossus supercomputer with Palantir's operational expertise and TWG Global's implementation capabilities, targeting CEO-level engagement to deploy hundreds of thousands of AI agents across enterprises, resulting in transformative productivity gains. Is PLTR Stock a Good Buy? Palantir reported strong financial results for Q1 2025, showcasing remarkable growth across key metrics. It generated $884 million in revenue, representing 39% year-over-year growth. U.S. operations drove exceptional performance, with total U.S. revenue surging 55% year-over-year to $628 million. U.S. commercial revenue grew 71% year-over-year to $255 million, surpassing a $1 billion annual run rate. The company closed 139 deals worth at least $1 million and booked a record U.S. commercial total contract value of $810 million, up 183% year-over-year. Profitability metrics were equally strong, with GAAP income from operations reaching $176 million (a 20% margin) and adjusted income from operations reaching $391 million (a 44% margin). Palantir generated $310 million in cash from operations and $370 million in adjusted free cash flow. CEO Alex Karp attributed success to delivering 'the operating system for the modern enterprise in the era of AI,' highlighting the company's early investment in AI platforms that were initially met with skepticism. Based on strong performance, Palantir raised full-year 2025 guidance, projecting total revenue growth of 36% and U.S. commercial revenue growth of 68%. It expects Q2 revenue to be between $934 million and $938 million. What Is the Target Price for PLTR Stock? The ongoing rally in PLTR stock means it now trades at a lofty price-earnings multiple of over 200x. Out of the 20 analysts tracking PLTR stock, three recommend 'Strong Buy,' 12 recommend 'Hold,' one recommends 'Moderate Sell,' and four recommend 'Strong Sell.' The average target price for PLTR stock is near $94, below the current price near $122.
CBC
an hour ago
- CBC
White House blames 'formatting issues' in health report that cited non-existent studies
Social Sharing The wide-ranging "Make America Healthy Again" (MAHA) report spearheaded by U.S. Health and Human Services Secretary Robert F. Kennedy Jr. cited hundreds of studies, but a closer look by the news organization NOTUS found that some of those studies did not actually exist. Asked about the report's problems on Thursday, White House press secretary Karoline Leavitt said the report will be updated. She did not directly respond to a question of whether artificial intelligence had been used to generate the 72-page report, which calls for increased scrutiny of the childhood vaccine schedule and decried America's food supply, pesticides and prescription drugs. "I understand there was some formatting issues with the MAHA report that are being addressed and the report will be updated." Leavitt told reporters during her briefing. "But it does not negate the substance of the report, which, as you know, is one of the most transformative health reports that has ever been released by the federal government." Leavitt said that the White House has "complete confidence" in Kennedy. NOTUS reported Thursday that seven of the more than 500 studies cited in the report did not appear to have ever been published, while its report said some studies were also misinterpreted in the MAHA report. Katherine Keyes, an epidemiology professor at the Columbia University Mailman School of Public Health, was cited in the report as the author of "Changes in mental health and substance use among US adolescents during the COVID-19 pandemic," which the report said was published in the medical journal JAMA Pediatrics. Report 'should be junked': public health official Keyes told Reuters that neither she nor the named co-authors of the paper had written it. According to Virginia Commonwealth University, psychiatry professor Robert L. Findling — who teaches at that school — did not author the article cited in the report as "Direct-to-consumer advertising of psychotropic medications for youth: A growing concern" in the Journal of Child and Adolescent Psychopharmacology. The studies attributed to Findling and Keyes no longer appeared in the MAHA report on the White House website as of Thursday evening. Kennedy has spent decades sowing doubt about the safety of vaccines, raising concerns within the scientific and medical communities over the policies he would pursue as health secretary. Since taking the role, thousands of workers at federal health agencies have been fired and billions cut from U.S. biomedical research spending — though at times in congressional testimony, Kennedy has professed a lack of knowledge of some of the layoffs. WATCH | Kennedy was confirmed, even after contentious confirmation: RFK Jr. grilled over vaccines, abortions at U.S. confirmation hearing 4 months ago Duration 2:06 U.S. health secretary nominee Robert F. Kennedy Jr. sparred with lawmakers over his controversial statements on vaccines and abortion at his first confirmation hearing. He also made several factual errors about how Medicaid and Medicare operate. The MAHA report is supposed to be used to develop policy recommendations that will be released later this year. The White House has requested a $500 million US boost in funding from Congress for the initiative. Georges C. Benjamin, executive director of the American Public Health Association, told the Washington Post that, "for all practical purposes, [the report] should be junked at this point." "It cannot be used for any policymaking. It cannon even be used for any serious discussion, because you can't believe what's in it. COVID, bird flu vaccine announcements questioned It was the latest development in a busy week for Kennedy and the department. On Tuesday, he announced in a brief video that COVID-19 vaccines are no longer recommended for healthy children and pregnant women — a move immediately questioned by several public health experts. A Centers for Diseases Control (CDC) advisory panel is set to meet in June to make recommendations about the fall shots, but Kennedy decided not to wait for the scientific panel's review. Food and Drug Administration Commissioner Dr. Marty Makary and Dr. Jay Bhattacharya, head of the National Institutes of Health, appeared in the video with Kennedy, but no one from CDC did. "There's no new data or information, just them flying by the seat of their pants," said Michael Osterholm, director of the University of Minnesota's Center for Infectious Disease Research and Policy. Some physicians and public health leaders expressed concern that Health and Human Services officials disregarded a scientific review process that has been in place for decades, in which experts — in public meetings — review current medical evidence and hash out the pros and cons of policy changes. "It's a dangerous precedent," said Osterholm. Among the problems, experts said, was the implication that the coronavirus isn't dangerous to pregnant women. During the height of the pandemic, deaths of women during pregnancy or shortly after childbirth soared to their highest level in 50 years. As well, pregnancy was on the list of health conditions that would qualify someone for a COVID-19 vaccination under FDA's new guidance framework announced just last week. "To say that they are not at any risk is simply incorrect," said Dr. Sean O'Leary of the American Academy of Pediatrics. As well, the The Trump administration this week cancelled $766 million US paid to Moderna for vaccine development. Moderna received $176 million US in July 2024 and $590 million in January. The January award would have supported a late-stage clinical trial that could have determined vaccine efficacy against pandemic viruses, including bird flu, a company spokesman said on Wednesday. H5N1 bird flu viruses spilled from wild bird into cattle in the U.S. last year, infecting hundreds of animals in several states. At least 70 people in the U.S. have been sickened by bird flu infections, mostly mild, but one person died.
